AGEs/RAGE in CKD: Irreversible metabolic memory road toward CVD?

European Journal of Clinical Investigation

Volumn 40, Issue 7, 2010, Pages 623-635

  Koyama, Hidenori ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products (AGEs); Chronic kidney disease (CKD); Endogenous secretory RAGE (esRAGE); Oxidative stress; Receptor for AGEs (RAGE); Soluble RAGE (sRAGE)

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AUTACOID; BIOLOGICAL MARKER;

ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE COURSE; HUMAN; KIDNEY FAILURE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GLOMERULAR FILTRATION RATE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 77953522847     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02298.x     Document Type: Review

References (137)

1. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974 290: 697 701.
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998 9: S16 23.
3. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001 12: 1516 1523.
4. USRDS. The United States Renal Data System. Am J Kidney Dis 2003 42: 1 230.
5. Nishimura M, Hashimoto T, Kobayashi H, Fukuda T, Okino K, Yamamoto N et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int 2004 66: 811 819.
6. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997 12: 718 723.
7. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005 16: 1141 1148.
8. Hase H, Tsunoda T, Tanaka Y, Takahashi Y, Imamura Y, Ishikawa H et al. Risk factors for de novo acute cardiac events in patients initiating hemodialysis with no previous cardiac symptom. Kidney Int 2006 70: 1142 1148.
9. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005 20: 1048 1056.
10. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 353: 238 248. (Pubitemid 41058323)
11. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009 360: 1395 1407.
12. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352: 837 853.
13. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359: 1577 1589.
14. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353: 2643 2653.
15. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med 2004 351: 1344 1346.
16. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981 211: 491 493.
17. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997 12: 255 258.
18. Canestrari F, Galli F, Giorgini A, Albertini MC, Galiotta P, Pascucci M et al. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994 91: 187 193.
19. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997 51: 1170 1181.
20. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004 24: 469 473.
21. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998 54: 1290 1295.
22. Galli F, Varga Z, Balla J, Ferraro B, Canestrari F, Floridi A et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int Suppl 2001 78: S148 54.
23. Kosch M, Levers A, Fobker M, Barenbrock M, Schaefer RM, Rahn KH et al. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant 2003 18: 1370 1375.
24. Diepeveen SH, Verhoeven GH, van der Palen J, Dikkeschei BL, van Tits LJ, Kolsters G et al. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 2004 98: c3 7.
25. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998 161: 2524 2532.
26. Fortuno A, Beloqui O, San Jose G, Moreno MU, Zalba G, Diez J. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production in patients with early chronic kidney disease. Kidney Int Suppl 2005 68: S71 5.
27. Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006 47: 42 50.
28. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996 21: 845 853.
29. Koyama H, Nishizawa Y. Cardiovascular complications in renal failure: implications of advanced glycation end-products and their receptor, RAGE. In: Miyata T, Eckardt KU, Nangaku M, editors. Oxidative Stress in Applied Basic Research and Clinical Practice 'Renal Disorders'.
30. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004 47: 1324 1330.
31. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005 16: 3687 3693.
32. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008 57: 1452 1457.
33. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998 95: 4630 4634.
34. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001 104: 1464 1470.
35. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999 99: 2434 2439.
36. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001 12: 2117 2124.
37. Kitahara T, Ono K, Tsuchida A, Kawai H, Shinohara M, Ishii Y et al. Impact of brachial-ankle pulse wave velocity and ankle-brachial blood pressure index on mortality in hemodialysis patients. Am J Kidney Dis 2005 46: 688 696.
38. Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999 142: 67 77.
39. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A et al. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994 91: 9441 9445.
40. Drueke TB, Nguyen Khoa T, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B. Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int Suppl 2001 78: S114 9.
41. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004 84: 1381 1478.
42. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P et al. Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 2006 66: 418 425.
43. Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Shoji T et al. Advanced glycation end-products, carotid atherosclerosis and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 2010 in press).
44. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int 2006 70: 218 224.
45. Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007 30: 107 112.
46. Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL. Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006 21: 1611 1617.
47. Wagner Z, Molnar M, Molnar GA, Tamasko M, Laczy B, Wagner L et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006 47: 294 300.
48. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002 62: 301 310.
49. Busch M, Franke S, Muller A, Wolf M, Gerth J, Ott U et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004 66: 338 347.
50. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome-the heart of the matter. Nephrol Dial Transplant 2002 17 (Suppl. 11 28 31.
51. Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis 2009 53: 298 309.
52. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992 267: 14987 14997.
53. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992 267: 14998 14004.
54. Xie J, Reverdatto S, Frolov A, Hoffmann R, Burz DS, Shekhtman A. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 2008 283: 27255 27269.
55. Matsumoto S, Yoshida T, Murata H, Harada S, Fujita N, Nakamura S et al. Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 2008 47: 12299 12311.
56. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97: 889 901.
57. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995 270: 25752 25761.
58. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000 405: 354 360.
59. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996 382: 685 691.
60. Sousa MM, Yan SD, Stern D, Saraiva MJ. Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. Lab Invest 2000 80: 1101 1110.
61. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003 198: 1507 1515.
62. Krieger M, Stern DM. Series introduction: multiligand receptors and human disease. J Clin Invest 2001 108: 645 647.
63. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001 108: 949 955.
64. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001 108: 261 268.
65. Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H et al. RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes 2006 55: 2510 2522.
66. Kankova K, Stejskalova A, Hertlova M, Znojil V. Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol Dial Transplant 2005 20: 1093 1102.
67. Prevost G, Fajardy I, Besmond C, Balkau B, Tichet J, Fontaine P et al. Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab 2005 31: 35 9.
68. Bierhaus A, Haslbeck KM, Humpert PM, Liliensiek B, Dehmer T, Morcos M et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004 114: 1741 1751.
69. Toth C, Rong LL, Yang C, Martinez J, Song F, Ramji N et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008 57: 1002 1017.
70. Xu D, Kyriakis JM. Phosphatidylinositol 3′-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products. J Biol Chem 2003 278: 39349 39355.
71. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994 269: 9889 9897.
72. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001 280: E685 94.
73. Dukic-Stefanovic S, Gasic-Milenkovic J, Deuther-Conrad W, Munch G. Signal transduction pathways in mouse microglia N-11 cells activated by advanced glycation endproducts (AGEs). J Neurochem 2003 87: 44 55.
74. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997 272: 16498 16506.
75. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001 50: 2792 2808.
76. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 2003 278: 34834 34844.
77. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995 96: 1395 1403.
78. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001 17: 436 443.
79. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105: 816 822.
80. Hou FF, Ren H, Owen WF Jr., Guo ZJ, Chen PY, Schmidt AM et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004 15: 1889 1896.
81. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B et al. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 2005 180: 333 340.
82. Linden E, Cai W, He JC, Xue C, Li Z, Winston J et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 2008 3: 691 698.
83. Greten J, Kreis I, Wiesel K, Stier E, Schmidt AM, Stern DM et al. Receptors for advance glycation end-products (AGE)-expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 1996 11: 786 790. (Pubitemid 26148246)
84. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000 275: 25781 25790.
85. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003 108: 1070 1077.
86. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004 24: 1266 1271.
87. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr., Chow WS et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998 4: 1025 1031.
88. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ Jr. et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2001 21: 905 910.
89. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006 185: 70 7.
90. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008 57: 2461 2469.
91. Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/-mice. J Clin Invest 2008 118: 183 194.
92. Ueno H, Koyama H, Shoji T, Kurato M, Fukumoto S, Tanaka S et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apo E-deficient mouse. Atherosclerosis 2010 in press).
93. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002 106: 2827 2835.
94. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005 16: 109 116.
95. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005 112: 2875 2882. (Pubitemid 41641683)
96. Bro S, Flyvbjerg A, Binder CJ, Bang CA, Denner L, Olgaard K et al. A neutralizing antibody against receptor for advanced glycation end products (RAGE) reduces atherosclerosis in uremic mice. Atherosclerosis 2008 201: 274 280.
97. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999 71: 159 170.
98. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003 370: 1097 1109.
99. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms-a result of regulated alternative splicing? Biochim Biophys Acta 2003 1630: 1 6.
100. Park IH, Yeon SI, Youn JH, Choi JE, Sasaki N, Choi IH et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 2004 40: 1203 1211.
101. Ding Q, Keller JN. Splice variants of the receptor for advanced glycosylation end products (RAGE) in human brain. Neurosci Lett 2005 373: 67 72.
102. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008 22: 1572 1580.
103. Kalea AZ, Reiniger N, Yang H, Arriero M, Schmidt AM, Hudson BI. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009 23: 1766 1774.
104. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005 83: 876 886.
105. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K et al. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 2006 55: 2245 2255.
106. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 2005 25: 879 882.
107. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004 279: 50019 50024.
108. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008 22: 3716 3727.
109. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008 283: 35507 35516.
110. Pullerits R, Brisslert M, Jonsson IM, Tarkowski A. Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1. Arthritis Rheum 2006 54: 3898 3907.
111. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005 25: 1032 1037. (Pubitemid 40627851)
112. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 2009 52: 705 714.
113. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2009 204: 288 292.
114. Koyama H, Yamamoto H, Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 2007 13: 625 635.
115. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata K, Hui L et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 2006 73: 158 165.
116. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005 25: 2587 2593.
117. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007 6: 9.
118. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Nakatani Y et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 2005 28: 2716 2721.
119. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T et al. Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 2008 5: 190 197.
120. Lu L, Pu LJ, Zhang Q, Wang LJ, Kang S, Zhang RY et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009 206: 540 545.
121. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006 49: 2756 2762.
122. Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006 47: 406 411.
123. Nishizawa Y, Koyama H. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease. J Ren Nutr 2008 18: 76 82.
124. Kalousova M, Bartosova K, Zima T, Skibova J, Teplan V, Viklicky O. Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation. Kidney Blood Press Res 2007 30: 31 7.
125. Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010 77: 225 231.
126. Koyama H, Shoji T, Fukumoto S, Shinohara K, Emoto M, Mori K et al. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 2007 27: 147 153.
127. Kosaki A, Hasegawa T, Kimura T, Iida K, Hitomi J, Matsubara H et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2004 89: 5423 5428.
128. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006 91: 4628 4634.
129. Gross S, van Ree RM, Oterdoom LH, de Vries AP, van Son WJ, de Jong PE et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation 2007 84: 659 663.
130. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005 16: 2363 2372.
131. Marx N, Walcher D, Ivanova N, Rautzenberg K, Jung A, Friedl R et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004 53: 2662 2668.
132. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002 16: 1928 1930.
133. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006 26: 2716 2723.
134. Tan KC, Chow WS, Tso AW, Xu A, Tse HF, Hoo RL et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 2007 50: 1819 1825.
135. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2009 209: 173 177.
136. Humpert PM, Kopf S, Djuric Z, Wendt T, Morcos M, Nawroth PP et al. Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 2006 29: 1111 1113.
137. Kalousova M, Jachymova M, Mestek O, Hodkova M, Kazderova M, Tesar V et al. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 2007 20: 2020 2026. (Pubitemid 47244776)